Active substance
Famciclovir
- SFDA 4
- US FDA 9
- Health Canada 6
- US price lines 3
- NHS prices 6
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FAMVIR 125MGTAB | 125 mg | Film-coated tablet · Oral use | 10 Blister | SAR 96.25 | NCE · Prescription | Atnahs Pharma UK Limited | Valid |
| FAMVIR 250MG TAB | 250 mg | Film-coated tablet · Oral use | 21 Blister | SAR 414.75 | NCE · Prescription | Atnahs Pharma UK Limited | Valid |
| Zostivr | 500 mg | Film-coated tablet · Oral use | 30 Blister | SAR 1100.00 | Generic · Prescription | Saudi Amarox | Valid |
| Zostivr | 250 mg | Film-coated tablet · Oral use | 30 Blister | SAR 550.00 | Generic · Prescription | Saudi Amarox | Valid |
Indications — CHI Daman Drug Formulary
CHICKENPOX (VARICELLA); HERPES SIMPLEX VIRUS (HERPES LABIALIS); HERPES ZOSTER (SHINGLES); HERPESVIRAL KERATITIS, ZOSTER KERATITIS, KERATITIS, VARICELLA KERATITIS; MULTIPLE MYELOMA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| FAMCICLOVIR | 125MG; 250MG; 500MG | tablet · oral | TEVA PHARMS | Prescription | 24 Aug 2007 |
| FAMCICLOVIR | 125MG; 250MG; 500MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 21 Mar 2011 |
| FAMCICLOVIR | 125MG; 250MG; 500MG | tablet · oral | MACLEODS PHARMS LTD | Prescription | 12 Jan 2012 |
| FAMCICLOVIR | 125MG; 250MG; 500MG | tablet · oral | HETERO LABS LTD V | Prescription | 10 Sep 2014 |
| FAMVIR | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | NOVARTIS | Discontinued | 29 Jun 1994 |
| FAMCICLOVIR | 125MG; 250MG; 500MG | tablet · oral | CIPLA | Discontinued | 21 Mar 2011 |
| FAMCICLOVIR | 125MG; 250MG; 500MG | tablet · oral | HIKMA PHARMS | Discontinued | 21 Mar 2011 |
| FAMCICLOVIR | 125MG; 250MG; 500MG | tablet · oral | NATCO PHARMA | Discontinued | 24 Mar 2011 |
| FAMCICLOVIR | 125MG; 250MG; 500MG | tablet · oral | APOTEX | Discontinued | 22 Jul 2011 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-FAMCICLOVIR | 02292025 | 125 MG | TABLET · ORAL | APOTEX INC |
| APO-FAMCICLOVIR | 02292041 | 250 MG | TABLET · ORAL | APOTEX INC |
| APO-FAMCICLOVIR | 02292068 | 500 MG | TABLET · ORAL | APOTEX INC |
| FAMVIR | 02177102 | 500 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
| FAMVIR | 02229110 | 125 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
| FAMVIR | 02229129 | 250 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FAMCICLOVIR 125 MG TABLET | $0.21439 | per EA | 23 Sep 2026 |
| US NADAC | FAMCICLOVIR 250 MG TABLET | $0.44249 | per EA | 23 Sep 2026 |
| US NADAC | FAMCICLOVIR 500 MG TABLET | $0.7878 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Famciclovir 125mg tablets | £53.45 | 10 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Famciclovir 250mg tablets | £148.25 | 15 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Famciclovir 250mg tablets | £207.55 | 21 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Famciclovir 250mg tablets | £553.46 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Famciclovir 500mg tablets | £269.07 | 14 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Famciclovir 500mg tablets | £641.21 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 18 Dec 2018 FAMVIR — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.